Efficacy of paroxetine on longitudinal ADL and QOL in post-stroke depression

我们对脑卒中后抑郁（PSD）患者给予选择性5-羟色胺再摄取抑制剂（SSRI）帕罗西汀治疗8周，并与尼麦角林对照治疗8个月。与对照组相比，在药物剂量期间给予帕罗西汀的组的抑郁症的严重程度有所改善，但在药物剂量结束时，步态和ADL能力没有发现差异。而帕罗西汀组有缩短住院时间的趋势。SSRI治疗PSD的剂量对患者的纵向ADL和QOL无影响。但早期诊断为PSD并给予SSRI可改善抑郁症状，并可缩短住院时间。

We administered paroxetine, one of the selective serotonin reuptake inhibitor (SSRI), or nicergoline as a control to patients with post-stroke depression (PSD) for eight weeks and evaluated the severity of depression, disabilities of stroke and QOL for eight months. The severity of depression was improved at the group which administered paroxetine during a medicine dosage period in comparison with the control group, but did not recognize a difference in ability of gait and ADL at the time of the medicine dosage end. However, it was the tendency that the hospitalization came to shorten in the group which administered paroxetine. The dosage of the SSRI for PSD did not affect longitudinal ADL and QOL. But it improves depression early to diagnose as PSD and administer SSRI, and it may shorten hospitalization.